Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTempest enters China CAR-T collaboration with Senlang, targeting Q4 2026 trial start
Filed July 22, 2026 · Period ending July 17, 2026 · ~1 min read
Key Changes
-
high
Tempest partnered with Senlang Biotechnology to develop TPST-4003, a CD7-targeted in vivo CAR-T candidate, beginning with a ~10-patient trial in myasthenia gravis or multiple sclerosis in China. First patient dosing expected Q4 2026, with initial safety and pharmacodynamic data as early as H1 2027.
Item 1.01 verify on EDGAR → -
medium
Tempest will pay Senlang $1.5M-$2.0M per product for development activities, with payments tied to milestones and a $2.0M cap per product unless additional amounts are approved in writing. Tempest retains worldwide, royalty-free rights to all trial data.
Item 1.01 verify on EDGAR → -
medium
Senlang received an exclusive option to negotiate China development and commercialization rights for TPST-4003 after completing the agreed trial data package. Tempest maintains global rights outside any future China license.
Item 1.01 verify on EDGAR → -
low
The collaboration has a three-year initial term with extension options. Tempest may terminate the agreement or any statement of work for convenience with 60 days' notice.
Item 1.01 verify on EDGAR →
Summary
Tempest Therapeutics entered a strategic collaboration with Hebei Senlang Biotechnology to advance TPST-4003, its CD7-targeted in vivo CAR-T candidate, into clinical development in China.
The partnership enables Tempest to expand the geographic reach of its CAR-T platform through a local partner with regional expertise in CD7-targeted therapies, while maintaining worldwide data rights and control over global development.
Senlang will conduct an investigator-initiated trial enrolling approximately 10 patients with myasthenia gravis or multiple sclerosis, with first dosing expected in Q4 2026 and initial safety and pharmacodynamic data as early as H1 2027. The financial structure caps Tempest's near-term commitment at $1.5M-$2.0M per product for development activities, with milestone-based payments providing cost control. Tempest retains worldwide, royalty-free rights to all trial data for research, regulatory, financing, and commercialization purposes. Senlang received an exclusive option to negotiate China commercialization rights after delivering the trial data package, potentially creating a future regional partnership while Tempest maintains global rights. The three-year agreement includes a 60-day termination-for-convenience provision, preserving Tempest's flexibility if the collaboration underperforms. For a clinical-stage company, the collaboration represents a capital-efficient path to generate proof-of-concept data for its in vivo CAR-T platform in autoimmune indications.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 17, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “Company” or “Tempest”), entered into a product development and investigator-initiated trial (“IIT”) collaboration agreement (“Collaboration Agreement”) with Heibei Senlang Biotechnology Co., Ltd., a company organized under the laws of the People’s Republic of China (“Senlang”). Pursuant to the Collaboration Agreement, the Company and Senlang agreed to collaborate with respect to product development activities and investigator-initiated trial activities in China for certain of the Company’s in vivo chimeric antigen receptor T cell (“CAR-T”) product candidates
Tempest entered a collaboration with Chinese partner Senlang to develop and conduct investigator-initiated trials in China for Tempest's CAR-T product candidates. The agreement enables Tempest to advance its CAR-T programs in China through a local partner with regional expertise.
Added in current filing · verify on EDGAR →
Under the agreement, Tempest and Senlang will collaborate to develop Tempest’s proprietary TPST-4003 product candidate, beginning with an IIT in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis (“MG”) or multiple sclerosis (“MS”). The Company expects first patient enrollment and dosing to occur in the fourth quarter of 2026.
The collaboration will begin with a trial of TPST-4003 in approximately 10 patients with myasthenia gravis or multiple sclerosis in China, with first patient dosing expected in Q4 2026. This represents Tempest's first clinical activity in China for its CAR-T platform and expands the geographic reach of its development program.
Event · Item 7.01 — Regulation FD Disclosure
Tempest Therapeutics issued a press release regarding matters described in Item 1.01, furnished under Regulation FD.
Added in current filing · verify on EDGAR →
On July 21, 2026, the Company issued a press release with respect to the matters described in Item 1.01 of this Current Report on Form 8-K, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.
The company issued a press release on July 21, 2026, regarding matters described in Item 1.01 of this 8-K. The press release is furnished as Exhibit 99.1. However, the 8-K body provided does not include Item 1.01 content or the Exhibit 99.1 press release text, so the specific subject matter of the disclosure cannot be determined from the available text.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”), a clinical-stage cell therapy company with extensive expertise in CD7-targeted CAR-T development and clinical translation. Under the agreement, Tempest and Senlang will collaborate to develop Tempest’s proprietary TPST-4003 product candidate, beginning with an investigator-initiated trial (“IIT”) in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis (“MG”) or multiple sclerosis (“MS”). The company expects first patient enrollment and dosing to occur in the fourth quarter of 2026.
Tempest has entered a strategic partnership with Senlang Biotechnology to develop TPST-4003, a next-generation in vivo CAR-T candidate. Senlang will conduct an investigator-initiated trial in China enrolling approximately 10 patients with myasthenia gravis or multiple sclerosis, with first patient dosing expected in Q4 2026. The agreement also grants Senlang an exclusive option to negotiate a definitive license agreement for TPST-4003 in China.
Added in current filing · view on EDGAR →
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications
TPST-4003 is Tempest's lead in vivo CAR-T product candidate that combines CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR structure. The candidate is designed to enable broad B-cell lineage depletion and immune reset, targeting autoimmune and oncology indications including myasthenia gravis and multiple sclerosis. This differentiates from other in vivo CAR-T approaches through its CD7-targeted delivery strategy designed to directly engage endogenous T-cell populations.
Added in current filing · view on EDGAR →
The initial trial is expected to assess the safety, cellular kinetics and pharmacodynamic activity of TPST-4003 in patients with MG or MS. Key assessments are expected to include treatment-emergent adverse events; the generation and expansion of peripheral blood CD4+ and CD8+ CAR-T cells and CD56+ CAR-NK cells; CAR transgene copy number; and the depth and kinetics of CD19+ B-cell depletion and B-cell subset reconstitution.
The investigator-initiated trial will assess safety, cellular kinetics, and pharmacodynamic activity of TPST-4003 in myasthenia gravis or multiple sclerosis patients. Key assessments include adverse events, CAR-T cell generation and expansion, transgene copy number, and B-cell depletion kinetics. Management expects initial safety and pharmacodynamic data from the first patients as early as the first half of 2027.
Added in current filing · view on EDGAR →
Additionally, the agreement grants Senlang an exclusive option to negotiate and enter into a definitive license agreement for TPST-4003 in China.
Under the collaboration agreement, Senlang has been granted an exclusive option to negotiate and enter into a definitive license agreement for TPST-4003 in China. This provides Senlang with potential commercialization rights in the Chinese market contingent on successful negotiation of definitive terms.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 22, 2026 · How we verify